scPharmaceuticals (SCPH)

scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX, which consists of a formulation of furosemide delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease. FUROSCIX also includes a subcutaneous loop diuretic that delivers IV equivalent diuresis at home, along with the FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. Its product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home. Additionally, the pipeline features SCP-111 Autoinjector, an investigational single-entity and drug-device combination product candidate consisting of a prefilled syringe containing SCP-111 preloaded into a mechanical autoinjector. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.